{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:21:13Z","timestamp":1790767273230,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.leukres.2008.09.026","type":"journal-article","created":{"date-parts":[[2008,11,5]],"date-time":"2008-11-05T10:59:12Z","timestamp":1225882752000},"page":"861-864","source":"Crossref","is-referenced-by-count":89,"title":["Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia"],"prefix":"10.1016","volume":"33","author":[{"given":"Walid","family":"Rasheed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Flaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.leukres.2008.09.026_bib1","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.ehj.2004.09.014","article-title":"Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology","volume":"25","author":"Galie","year":"2004","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.leukres.2008.09.026_bib2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.rmed.2006.11.022","article-title":"Diagnosis and management of pulmonary hypertension over the past 100 years","volume":"101","author":"van Wolferen","year":"2007","journal-title":"Respir Med"},{"issue":"8","key":"10.1016\/j.leukres.2008.09.026_bib3","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood.V97.8.2406","article-title":"A model of human p210(bcr\/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR\/ABL-containing retroviral vector","volume":"97","author":"Zhao","year":"2001","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.leukres.2008.09.026_bib4","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/0008-5472.CAN-03-3656","article-title":"Effect of mutational inactivation of tyrosine kinase activity on BCR\/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors","volume":"64","author":"Ramaraj","year":"2004","journal-title":"Cancer Res"},{"issue":"25","key":"10.1016\/j.leukres.2008.09.026_bib5","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quintas-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2008.09.026_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2008.03.027","article-title":"Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib","author":"Bajel","year":"2008","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.leukres.2008.09.026_bib7","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2008.09.026_bib8","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.leukres.2008.09.026_bib9","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"Suppl. 10","key":"10.1016\/j.leukres.2008.09.026_bib10","doi-asserted-by":"crossref","first-page":"x274","DOI":"10.1093\/annonc\/mdl273","article-title":"Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors","volume":"17","author":"Hochhaus","year":"2006","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.leukres.2008.09.026_bib11","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr\u2013Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.leukres.2008.09.026_bib12","first-page":"736","article-title":"Dasatinib or high-dose imatinib for patients with chronic-phase chronic myeloid leukemia resistant to standard-dose imatinib: 2-year follow-up data from START-R (CA180-017)","volume":"110","author":"Kantarjian","year":"2007","journal-title":"ASH Annu Meeting Abstr"},{"issue":"8","key":"10.1016\/j.leukres.2008.09.026_bib13","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series","volume":"176","author":"Bergeron","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.leukres.2008.09.026_bib14","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"de Lavallade","year":"2008","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.leukres.2008.09.026_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr\u2013Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.leukres.2008.09.026_bib16","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR\u2013ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2008.09.026_bib17","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR\u2013ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2008.09.026_bib18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/ncpcardio0890","article-title":"Pulmonary arterial hypertension: current therapeutic strategies","volume":"4","author":"Puri","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.leukres.2008.09.026_bib19","doi-asserted-by":"crossref","first-page":"L826","DOI":"10.1152\/ajplung.00199.2002","article-title":"Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus","volume":"284","author":"Balasubramaniam","year":"2003","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"4 Pt 1","key":"10.1016\/j.leukres.2008.09.026_bib20","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1164\/ajrccm.162.4.2003124","article-title":"Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy","volume":"162","author":"Eddahibi","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.leukres.2008.09.026_bib21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1183\/09031936.98.11030554","article-title":"Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients","volume":"11","author":"Humbert","year":"1998","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.leukres.2008.09.026_bib22","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/thx.2006.064097","article-title":"Long term imatinib treatment in pulmonary arterial hypertension","volume":"61","author":"Souza","year":"2006","journal-title":"Thorax"},{"issue":"13","key":"10.1016\/j.leukres.2008.09.026_bib23","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMc051946","article-title":"Imatinib for the treatment of pulmonary arterial hypertension","volume":"353","author":"Ghofrani","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.leukres.2008.09.026_bib24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.7326\/0003-4819-145-2-200607180-00020","article-title":"Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension","volume":"145","author":"Patterson","year":"2006","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.leukres.2008.09.026_bib25","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.leukres.2008.09.026_bib26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/(SICI)1096-8652(199902)60:2<130::AID-AJH8>3.0.CO;2-Z","article-title":"Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases","volume":"60","author":"Garcia-Manero","year":"1999","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.leukres.2008.09.026_bib27","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1378\/chest.120.3.801","article-title":"Unexplained pulmonary hypertension in chronic myeloproliferative disorders","volume":"120","author":"Dingli","year":"2001","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.leukres.2008.09.026_bib28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijcard.2003.08.013","article-title":"Functional and morphological cardiac changes in myeloproliferative disorders (clinical study)","volume":"97","author":"Kadikoylu","year":"2004","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.leukres.2008.09.026_bib29","first-page":"1779","article-title":"Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders","volume":"98","author":"Gupta","year":"2006","journal-title":"J Natl Med Assoc"},{"issue":"2","key":"10.1016\/j.leukres.2008.09.026_bib30","first-page":"245","article-title":"Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders","volume":"89","author":"Garypidou","year":"2004","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.leukres.2008.09.026_bib31","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1080\/10428190701493928","article-title":"Pulmonary hypertension in patients with essential thrombocythenia and reactive thrombocytosis","volume":"48","author":"Altintas","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.leukres.2008.09.026_bib32","first-page":"1029","article-title":"Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP) accelerated phase (AP) or blast crisis (BC)","volume":"110","author":"Giles","year":"2007","journal-title":"ASH Annu Meeting Abstr"},{"issue":"2","key":"10.1016\/j.leukres.2008.09.026_bib33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2006-07-035493","article-title":"Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure","volume":"109","author":"Quintas-Cardama","year":"2007","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608004220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608004220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:50:38Z","timestamp":1684619438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212608004220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0145212608004220"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2008.09.026","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}